Sign up
Pharma Capital

NetScientific's Glycotest subsidiary granted Japanese patent

The patent protects fucosylated kininogen - a key biomarker in the Glycotest's lead HCC Panel test for early-stage liver cancer.
Patents
Glycotest is the second NetScientific company this week to beef-up its patent protection

Glycotest, a portfolio company of NetScientific PLC (LON:NSCI), has been granted a patent in Japan over a biomarker for early-stage liver cancer.

The patent expands Glycotest's patent portfolio, which stands at 10 previously granted or allowed patents, protecting multiple aspects of Glycotest's proprietary liver disease diagnostic platform, including more than 50 unique glycoprotein biomarkers - measurements of a biological state - and the assay technology required to interpret them.

READ: NetScientific portfolio company Wanda gets US patent to further protect its core technology

These patents have been licenced exclusively on a worldwide basis to Glycotest by Drexel University College of Medicine and the Blumberg Institute of the Hepatitis B Foundation, both located in the Philadelphia area.

NetScientific holds an 87.5% stake in Glycotest, or 67% on a fully diluted basis.

READ: NetScientific positioned for continued commercial momentum

François Martelet, chief executive of intellectual property commercialisation company NetScientific PLC and chairman of Glycotest, said: "We are very pleased to announce further strengthening of the IP landscape controlled by Glycotest in the field of liver diagnostics and we expect further positive developments for the intellectual property portfolio in the future. We also look forward to further clinical validation of the Glycotest platform in H2 2017."

John-H.jpg
Why Invest In Netscientific PLC? Read More Here

Register here to be notified of future NSCI Company articles
View full NSCI profile

Netscientific PLC Timeline

View All

Related Articles

Antibiotics
US Food & Drug administration approval is yet to be granted but iclaprim, which has fast-track status, is closing in on the promised land.
generic pill and bottle shot to denote Alliance's products
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.